AbbVie ABBV is set to report fourth-quarter and full-year 2024 earnings on Jan. 31, before the opening bell. The Zacks ...

The US Food and Drug Administration (FDA) has approved AbbVie's VYALEV (foscarbidopa and foslevodopa) to treat motor ...

AbbVie has finally claimed FDA approval for its advanced Parkinson's disease therapy Vyalev, 18 months after the US regulator turned it down with a request for more data. Now, Vyalev (foscarbidopa ...

In last year's update, AbbVie raised the combined 2027 net sales guidance for Skyrizi and Rinvoq by $6 billion to $27 billion ...

MM PD market growth will be driven by advancements in innovative therapies, including the first DMTs, and a growing patient ...

Medscape Medical News, October 30, 2024 Alert FDA OKs Novel Levodopa-Based Regimen for Parkinson’s Vyalev (AbbVie) is the first and only subcutaneous 24-hour continuous infusion of levodopa ...